Title
Efficacy and Safety of L Arginine to Prevent Preeclampsia
Efficacy and Safety of L Arginine to Prevent Preeclampsia in High Risk Pregnancies
Phase
Phase 3Lead Sponsor
Hospital Civil Juan I. MenchacaStudy Type
InterventionalStatus
Completed No Results PostedIndication/Condition
PreeclampsiaIntervention/Treatment
arginine ...Study Participants
96Randomized double-blind controled clinical trial to assess the efficacy and safety of L-arginine to prevent preeclampsia.
applied to pregnant women with risk factors for preeclampsia. the main result was the development of preeclampsia as well as side effects to taking l arginine besides perinatal outcomes
Two groups were formed. one received L arginine 3 grams orally at day from the 20th week of pregnancy. the other group received placebo.
Each three weeks were evaluated in search of high blood pressure and proteinuria.
The follow-up was until the end of pregnancy and two weeks after this
L arginine is a basic amino-acid precursor of nitric oxide main vasodilator.
calcined magnesia
were administered 5 capsules per day each capsule contained 600 mg of magnesia calcinada. Duration: from week 20th of pregnancy until the end of the same. dose was administered as follows: two capsules in the morning at breakfast and three capsules at night in dinner.
were administered 5 capsules per day each capsule contained 600 mg of L arginine. Duration: from week 20th of pregnancy until the end of the same dose was administered as follows: two capsules in the morning at breakfast and three capsules at night in dinner.
Inclusion Criteria: one or more risk factors for developing preeclampsia (nulliparous, previous history of preeclampsia, chronic hypertension, BMI ≥30) Exclusion Criteria: pregnant women carriers of chronic renal failure pre gestational diabetes multiple pregnancy and were removed for some reason they received medication that would interfere with the interpretation of results (aspirin)
